<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2790-8305</journal-id>
<journal-title><![CDATA[Revista Científica CMDLT]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cien CMDLT]]></abbrev-journal-title>
<issn>2790-8305</issn>
<publisher>
<publisher-name><![CDATA[Centro Médico Docente La Trinidad]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2790-83052022000100203</article-id>
<article-id pub-id-type="doi">10.55361/cmdlt.v16i1.140</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Impacto de las Herramientas tecnológicas en Diabetes sobre la aparición de complicaciones crónicas en pacientes que viven con Diabetes mellitus tipo 1 que acuden a la consulta de Endocrinología CMDLT]]></article-title>
<article-title xml:lang="en"><![CDATA[Impact of Technological Tools in Diabetes on the appearance of chronic complications in patients living with type 1 Diabetes mellitus who attend the CMDLT Endocrinology consultation at CMDLT]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vilera]]></surname>
<given-names><![CDATA[Natacha]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carrera]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva de Casanova]]></surname>
<given-names><![CDATA[Marínés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Médico Docente La Trinidad (CMDLT)  ]]></institution>
<addr-line><![CDATA[Caracas ]]></addr-line>
<country>Venezuela</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Médico Docente La Trinidad (CMDLT)  ]]></institution>
<addr-line><![CDATA[Caracas ]]></addr-line>
<country>Venezuela</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro Médico Docente La Trinidad (CMDLT)  ]]></institution>
<addr-line><![CDATA[Caracas ]]></addr-line>
<country>Venezuela</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>16</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://ve.scielo.org/scielo.php?script=sci_arttext&amp;pid=S2790-83052022000100203&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://ve.scielo.org/scielo.php?script=sci_abstract&amp;pid=S2790-83052022000100203&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://ve.scielo.org/scielo.php?script=sci_pdf&amp;pid=S2790-83052022000100203&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El manejo de los pacientes que viven con diabetes tipo 1 es complejo no solo por el tratamiento farmacológico sino el impacto psicosocial que esto implica, la presencia de complicaciones resta calidad de vida y genera mayor costo a nivel de salud, el uso de la tecnología en diabetes ha demostrado mejor control metabólico en cuanto a disminución de HbA1C que se ha relacionado positivamente con la disminución de complicaciones tanto microvasculares como microvasculares. En este estudio se intenta conocer el Impacto de las herramientas tecnológicas en Diabetes sobre la aparición de complicaciones crónicas en pacientes que viven con DMT1 que acuden a la consulta de Endocrinología del CMDLT.  Métodos: Estudio observacional, analítico, cohorte retrospectivo tipo 1, que incluyó 39 pacientes, se recopilo la data usando una encuesta realizada en la consulta.  Resultados: La HbA1c es un factor determinante sobre el desarrollo de complicaciones en pacientes con diabetes tipo 1 (p: 0.014), encontrando un valor de HbA1c de 10,32 % ± 2,55 % en el grupo sin tecnología y un valor de HbA1c de 7,69 % ± 1,51 en el grupo con tecnología, sin embargo, un punto de corte de HbA1c mayor a 8% anula la relación entre el uso o no de tecnología y el desarrollo de complicaciones.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The management of patients living with type 1 diabetes is complex not only because of the pharmacological treatment but also because of the psychosocial impact that this implies, the presence of complications reduces quality of life and increases costs, the use of technology in diabetes has shown better metabolic control with a decrease in HbA1C that has been positively related to the decrease in both microvascular and microvascular complications. This study tries to find the Impact of the use of technology in Diabetes on the appearance of chronic complications in patients with T1DM who are attended at the CMDLT Endocrinology department.  Methods: Observational, analytical, retrospective type 1 cohort study, with 39 patients, the data was collected using a survey carried out during the patients visit.  Result: HbA1c is a determining factor on the development of complications in patients with type 1 diabetes (p: 0.014), finding an HbA1c value of 10.32% ± 2.55% in the group without technology and a HbA1c value of 7.69% ± 1.51 in the group with technology, however a cut-off point of HbA1c greater than 8% cancels the relationship between the use or not of technology and the development of complications.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Diabetes Mellitus tipo 1]]></kwd>
<kwd lng="es"><![CDATA[tecnología en diabetes]]></kwd>
<kwd lng="es"><![CDATA[complicaciones crónicas de Diabetes]]></kwd>
<kwd lng="es"><![CDATA[HbA1c]]></kwd>
<kwd lng="es"><![CDATA[control metabólico]]></kwd>
<kwd lng="en"><![CDATA[Type 1 Diabetes Mellitus]]></kwd>
<kwd lng="en"><![CDATA[technology in Diabetes]]></kwd>
<kwd lng="en"><![CDATA[chronic complications in Diabetes]]></kwd>
<kwd lng="en"><![CDATA[A1c]]></kwd>
<kwd lng="en"><![CDATA[metabolic control]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Atlas de Diabetes de la IDF]]></source>
<year>2019</year>
<edition>Novena</edition>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nieto Martínez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio venezolano de salud cardio metabólica]]></article-title>
<source><![CDATA[Med Interna Sociedad Venezolana de Medicina Interna]]></source>
<year>2018</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>30-4</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nathan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1993</year>
<volume>329</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>977-86</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sam]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential influences of social support on app use for diabetes self-management - a mixed methods approach]]></article-title>
<source><![CDATA[BMC Medical Informatics and Decision Making]]></source>
<year>2020</year>
<volume>20</volume>
<numero>151</numero>
<issue>151</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berget]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Use of Technology in Managing Diabetes in Youth Part 2-Insulin Pump Technologies: Information and Tips for the School Nurse]]></article-title>
<source><![CDATA[NASN School Nurse]]></source>
<year>2020</year>
<volume>35</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>188-95</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toschi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benefits and Challenges of Diabetes Technology Use in Older Adults]]></article-title>
<source><![CDATA[Endocrinol Metab Clin North Am]]></source>
<year>2020</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>57-67</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>CEM RDL</collab>
<article-title xml:lang=""><![CDATA[Diabetes Technology: Standards of Medical Care in Diabetes]]></article-title>
<source><![CDATA[ADA]]></source>
<year>2019</year>
<volume>42</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>571-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kublin]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Using Additional Readers for Flash Glucose Monitoring System on Metabolic Control, Safety, and the Incidence of Complications in Patients With Diabetes Mellitus]]></article-title>
<source><![CDATA[J Diabetes Sci Technol]]></source>
<year>2021</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>600-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pati]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and pattern of co morbidity among type2 diabetics attending urban primary healthcare centers at Bhubaneswar (India)]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2017</year>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schiel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Technology in Diabetes Treatment: Update and Future]]></article-title>
<source><![CDATA[Artif Organs]]></source>
<year>2018</year>
<volume>42</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1017-27</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wysocki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of Measures of Satisfaction with and Impact of Continuous and Conventional Glucose Monitoring]]></article-title>
<source><![CDATA[Diabetes Technology &amp; Therapeutics]]></source>
<year>2010</year>
<volume>12</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>679-84</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Racial-Ethnic Disparities in Diabetes Technology use Among Young Adults with Type 1 Diabetes]]></article-title>
<source><![CDATA[Diabetes Technol Ther]]></source>
<year>2021</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>306-13</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosland]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[When is social support important? The association of family support and professional support with specific diabetes self-management behaviors]]></article-title>
<source><![CDATA[J Gen Intern Med]]></source>
<year>2008</year>
<volume>23</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1992-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grassi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical features and management of 205 adults with type 1 diabetes mellitus]]></article-title>
<source><![CDATA[Rev. méd. Chile]]></source>
<year>2019</year>
<volume>147</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>451-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kubiak]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychosocial aspects of diabetes technology]]></article-title>
<source><![CDATA[Diabetic Medicine]]></source>
<year>2020</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>448-54</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Review of Blood Glucose Monitor Accuracy]]></article-title>
<source><![CDATA[Diabetes Technol Ther]]></source>
<year>2018</year>
<volume>20</volume>
<numero>12</numero>
<issue>12</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosland]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[When is social support important? The association of family support and professional support with specific diabetes self-management behaviors]]></article-title>
<source><![CDATA[J Gen Intern Med]]></source>
<year>2008</year>
<volume>23</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1992-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Litwak]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[[Continuous glucose monitoring. Utility and indications]]]></article-title>
<source><![CDATA[Medicina]]></source>
<year>2019</year>
<volume>79</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44-52</page-range><publisher-loc><![CDATA[B Aires ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franklin]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influences on Technology Use and Efficacy in Type 1 Diabetes]]></article-title>
<source><![CDATA[J Diabetes Sci Technol]]></source>
<year>2016</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>47-55</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreno-Ferández]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[García-Seco]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera-Moraleda]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world outcomes of insulin pump compared to multiple daily injection therapy in adult type 1 diabetes mellitus patients in a Mediterranean scenario]]></article-title>
<source><![CDATA[Int J Diabetes Dev Ctries]]></source>
<year>2021</year>
<volume>41</volume>
<page-range>259-65</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lind]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pivodic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Svensson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ólafsdóttir]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Wedel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ludvigsson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2019</year>
<volume>366</volume>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
